Publications – Agios Pharmaceuticals, Inc.

Year

Dec 12, 2022

Mitapivat Improves Markers of Hemolysis and Erythropoiesis in Patients with Pyruvate Kinase Deficiency Irrespective of Hemoglobin Response

Dec 11, 2022

Long-term Improvements in Patient-reported Outcomes in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat

Dec 11, 2022

Long-term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat

Dec 11, 2022

Comorbidities and Complications in Pediatric Patients with Pyruvate Kinase Deficiency Enrolled in the Peak Registry / Peak Pediatric Comorbidities

Dec 11, 2022

Mitapivat in Children with Pyruvate Kinase Deficiency Who Are Regularly Transfused

Dec 11, 2022

Age of Onset of Complications in Patients with Pyruvate Kinase Deficiency: Analysis from the Peak Registry

Dec 11, 2022

ACTIVATE-Kids: Mitapivat in Children with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Dec 11, 2022

Clinical Burden of Alpha- and Beta-thalassemia Compared to Matched Controls in the Real-world Setting

Dec 11, 2022

AG-946 Normalizes Glycolysis and Improves Red Cell Indices in a Humanized Sickle Cell Mouse Model

Dec 11, 2022

PKLR Variants Associated with Acute Pain in Sickle Cell Disease Influence ATP Concentrations in Red Blood Cells

Dec 11, 2022

Results from the Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers

Dec 10, 2022

Next Generation Sequencing for the Diagnosis of Hereditary Hemolytic Anemias Including Pyruvate Kinase Deficiency: Report from a No-cost Diagnostic Program

Dec 10, 2022

Mitapivat Improves Iron Overload in Patients with Pyruvate Kinase Deficiency

Dec 10, 2022

Mitapivat Improves Markers of Erythropoietic Activity in Long-term Study of Adults with Alpha- or Beta-non-transfusion-dependent Thalassemia

Dec 10, 2022

Characterizing the Clinical, Health-related Quality of Life and Economic Burden of Alpha-thalassemia: A Systematic Literature Review and Evidence Gaps Assessment

Dec 10, 2022

Effects of Pyruvate Kinase Activators on Red Blood Cell Rheology, Sickling and Senescence in Sickle Cell Disease

Dec 10, 2022

Untargeted Metabolomics in Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat

Dec 10, 2022

The Pyruvate Kinase Activator Mitapivat Improves Red Blood Cell Deformability and Sickling Kinetics in Adult Patients with Sickle Cell Disease

Dec 10, 2022

Activating Pyruvate Kinase Improves Red Blood Cell Integrity by Reducing Band3 Tyrosine Phosphorylation

Dec 10, 2022

A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-risk Myelodysplastic Syndromes

Aug 18, 2022

Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial

Source

The Lancet Haematology

Aug 13, 2022

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study

Source

The Lancet

Jun 11, 2022

Evidence of Noninferiority of Mitapivat Versus Splenectomy in Murine Hereditary Spherocytosis

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Long-term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults With Non–transfusion-dependent Alpha- or Beta-thalassemia

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Comorbidities and Complications Across Genotypes in Adult Patients With Pyruvate Kinase Deficiency: Analysis From the Peak Registry

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Mitapivat Decreases the Need for Transfusions Secondary to Poorly Tolerated Anemia and Acute Events Compared to Placebo in Patients With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-term Treatment With Mitapivat

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained Over Time in Patients With Pyruvate Kinase Deficiency Treated With Mitapivat in a Long-term Extension Study

Source

EHA 2022 Annual Meeting

Jun 10, 2022

ACTIVATE-kidsT: Mitapivat in Children With Pyruvate Kinase Deficiency Who Are Regularly Transfused

Source

EHA 2022 Annual Meeting

Jun 10, 2022

ACTIVATE-kids: Mitapivat in Children With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Long-term Treatment With Oral Mitapivat Is Associated With Normalization of Hemoglobin Levels in Patients With Pyruvate Kinase Deficiency

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Characterizing Iron Overload by Age in Patients Diagnosed with Pyruvate Kinase Deficiency – a Descriptive Analysis from the Peak Registry

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Mitapivat Improves Ineffective Erythropoiesis and Reduces Iron Overload in Patients With Pyruvate Kinase Deficiency

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Improvements in Patient-Reported Outcomes in Mitapivat-treated Patients With Pyruvate Kinase Deficiency: A Descriptive Analysis From the Phase 3 ACTIVATE Trial

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Systematic Literature Review of Health-related Quality of Life Burden in Patients Across the Spectrum of Thalassemia

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Pharmacokinetic Modeling and Simulation to Support Mitapivat Dose Selection Used in Pediatric Phase III Studies

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Healthcare Resource Utilization of Adult Patients With Pyruvate Kinase Deficiency: A Real World Study Using US Veterans Health Administration Data

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Pharmacodynamic Effects of AG-946, a Highly Potent Novel Activator of Pyruvate Kinase, In Ex Vivo Treatment of Red Blood Cells From Sickle Cell Disease Patients

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Follow-up Results of a Phase 2 Study Assessing the Safety and Efficacy of Mitapivat Treatment, an Oral Pyruvate Kinase Activator, for up to 60 Weeks in Subjects With Sickle Cell Disease

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Adapting Patient Educational Approaches in Pyruvate Kinase Deficiency: Europe and North America Findings From the AAC Patient and Caregiver Survey

Source

EHA 2022 Annual Meeting

May 16, 2022

A Phase 1 Dose Escalation Study of the Pyruvate Kinase Activator Mitapivat (AG-348) in Sickle Cell Disease

Source

Blood

Apr 14, 2022

Mitapivat versus Placebo for Pyruvate Kinase Deficiency

Source

New England Journal of Medicine

For details on our former oncology programs, visit https://www.servier.us/.